Research, Charts & Company Announcements
Research Tree provides access to ongoing research coverage, media content and regulatory news on PAYPAL HOLDINGS INC. We currently have 0 research reports from 0 professional analysts.
|24Nov16 11:00||PRN||Canadian E-Retailers to Benefit From Buy-Local Holiday Shopping Trend|
|07Nov16 10:15||PRN||Research Reports on Credit Services Equities -- PayPal, LendingClub, Visa, and Synchrony Financial|
|02Nov16 01:33||PRN||Latest Innovation in Payments and Financial Services Showcased at The Money20/20 Global Event|
|20Oct16 02:31||PRN||Covered Call reports for Valeant Pharmaceuticals, PayPal Holdings Inc., SolarCity, Skechers and The Goldman Sachs Group include trade ideas that offer returns of 20% or more!|
|05Oct16 01:45||PRN||Mobile Apps Continue Pace as Fastest Growing E-Commerce Channel With Astounding Growth In Sales This Year|
|26Sep16 09:05||PRN||Lending Club Names Russell S. Elmer as General Counsel|
|23Sep16 02:31||PRN||Covered Call reports for Bristol-Myers Squibb, First Solar, Corrections Corporation of America, PayPal Holdings Inc. and Walgreens Boots Alliance include trade ideas that offer returns of 20% or more!|
Frequency of research reports
Research reports on
PAYPAL HOLDINGS INC
PAYPAL HOLDINGS INC
Panmure Morning Note 30-11-2016
30 Nov 16
RPC, the international plastics products design and engineering group, has delivered yet another strong set of results (1H17 EBITDA +65%, EPS +45%). At the interim stage PBT was +66% (materially better than we had forecast). Topline growth has principally being driven by acquisitions (GCS + BPI), though organic remains a feature (and crucially remains at levels consistent with FY16). The two recent acquisitions have quickly been assimilated into the panEuropean platform and management has raised cost synergy guidance (again).
N+1 Singer - Morning Song 30-11-2016
30 Nov 16
Sanderson has delivered full year results in line with expectations and the 19 October trading update after a strong finish to the year compensated for a slower start. A healthy level of pre-contracted recurring revenue (50%), incremental sales to existing customers and new customer wins at higher average order values helped deliver solid revenue growth in both the Digital Retail (+9%) and Enterprise (+12%) divisions. A decent order book and good sales momentum suggest that the company is on track to deliver on unchanged profit expectations for the current year. We continue to view the valuation (FY17 EV/EBITDA 8.6x) as undemanding given an attractive combination of accelerating growth potential, strong cash generation and growing dividends.
Panmure Morning Note 02-12-16
02 Dec 16
Today James Halstead will be holding its 101st AGM. Trading during the first part of FY17 has been mixed, with some notable challenges. However, movements in FX (i.e. weak sterling) is boosting reported earnings, offsetting UK volume trends and pricing pressures. Whilst earnings are likely to be second half weighted, the picture is in-line with expectations and we are leaving our FY17 PBT estimates unchanged (£47.4m in FY17 vs £45.4m FY16).
02 Dec 16
On 30 September 2016, when the company announced its full year results, it reported that the UK business had seen a slow start to the year, with particular weakness in repair and renewal spending by the NHS as well as “reticence” in the education sector. However, with the UK only representing about a third of the business, this weakness was expected to be more than offset by the positive effect of a weakened sterling on its overseas business, given the benefits for competitiveness and margins.
Small Cap Breakfast
29 Nov 16
Asia Pacific Investment Partner - the research-driven emerging and frontier markets real estate development business intends to float on AIM and conduct a placing in December RM Secured Direct Lending - The secured direct lending fund intends to float on the Main Market on 15 December raising up to £100m Diversified Oil & Gas— Schedule One now out. $60m to be raised. Expected admission 6 December. Creo Medical Group —UK based medical device company focused on surgical endoscopy, a recent development in minimally invasive surgery. Admission due 7 December. Fundraising details TBA.